The survival aspects for osteosarcoma patients have remained stable for over 25 years; indicating the importance of developing new, novel, treatment strategies.
The spread of cancer to other areas of the body (known as metastasis) is a large factor in worsening patient prognosis. Therefore targeting the aspect of osteosarcoma metastasis aims to provide a better long-term outlook for patients.
Professor Salter, and his PhD student Harrison Worrell, have determined that a protein known as NG2/CSPG4 is expressed in osteosarcoma cell-lines and patient tumour samples. NG2/CSPG4 is known to be associated with tumour growth, progression, spread and resistance to chemotherapy and radiotherapy in other tumour types.
This study aims to further investigate NG2/CSPG4 in the progression of osteosarcomas specifically. Determining if targeting this protein therapeutically may reduce treatment resistance and the spread of osteosarcoma while leading to more promising survival aspects for patients.
This project will act as a proof-of-principle study to support the clinical development of anti-NG2/CSPG4 therapies in the future; using targeting antibodies against NG2/CSPG4 to deliver toxins to the tumour while having limited effects on healthy tissue to reduce any treatment side-effects.